Genetic Signatures Limited (ASX: GSS) - ETF Exposure

- Current share price for GSS : $0.058

Genetic Signatures Limited (GSS) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is engaged in the research and development into identifying and commercialization of molecular diagnostics products to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces.

GSS General Information ⁺

ASX Code	GSS
Website	http://www.geneticsignatures.com
Industry/Sector	Life Sciences Tools & Services
Market Cap ($M)	13
GSS Share Price	$0.058
Day High	$0.058
Day Low	$0.058
Last Close	$0.058
GSS Share Price Movement	- ( No change )

Prices as at 16:40, 7 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to GSS

Genetic Signatures Limited (GSS) is held across 1 ETF spanning strategies that include life sciences tools & services exposure . Its weighting in those funds means performance can have an outsized influence - when GSS moves, funds like IMPQ that hold it can move with it.

For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 0.3% to GSS , while the average exposure across all 1 ETF that hold it is around 0.3% .

Top ETF holdings

eInvest Better Future (Managed Fund) (IMPQ) ~ 0.3%

Last updated: ETF data and holdings as at 9 August 2026

Own GSS directly or through an ETF?

How does holding Genetic Signatures Limited (GSS) shares directly compare to ETFs that include it?

	GSS Direct	IMPQ ASX
Holdings	1 company	41 holdings
GSS Weight	100%	0.3%
Diversification	Single Stock	Broad
Annual Cost	Brokerage only	0.89% p.a.
Approx. Yield	-	2.05%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not GSS's direct yield. Annual cost uses each ETF's MER.

GSS Exposure on $10,000 investment

How a $10,000 investment in Genetic Signatures Limited (GSS) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Genetic Signatures Limited (GSS)	Direct share	$0.058	-1.69%	-$169	$9,831
eInvest Better Future (Managed Fund) (IMPQ)	Equity - Australia Small/Mid Cap	$4.390	4.03%	+$403	$10,403

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Genetic Signatures Limited (GSS) ETFs

1 ETF hold Genetic Signatures Limited (GSS).

ETF	GSS Weight	MER	Yield
eInvest Better Future (Managed Fund) (IMPQ)	0.3%	0.89%	2.05%

Genetic Signatures Limited (GSS) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
Final	0.12¢	0%	27 Aug 1996	30 Sep 1996	-	-	-

See all dividends from Genetic Signatures Limited (GSS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Genetic Signatures Limited (GSS) price-sensitive announcements

GSS - Quarterly Activities/Appendix 4C Cash Flow Report

Genetic Signatures Limited reported its quarterly activities and Appendix 4C cash flow for

Genetic Signatures Limited (GSS)
23 Jul 2026 | 2:11 PM

GSS - GSS responds to the BCAL Diagnostics Announcement

Genetic Signatures Limited, in response to BCAL Diagnostics' announcement about acquiring

Genetic Signatures Limited (GSS)
2 Jul 2026 | 2:41 PM

GSS - BDX: BCAL to Acquire Shares in Genetic Signatures

BCAL Diagnostics Limited announced their acquisition of 23,173,644 shares, equating to 10.

Genetic Signatures Limited (GSS)
2 Jul 2026 | 10:04 AM

GSS - Quarterly Activities/Appendix 4C Cash Flow Report

Genetic Signatures Limited reported $3 million in sales for Q3 FY2026, largely due to seas

Genetic Signatures Limited (GSS)
29 Apr 2026 | 8:22 AM

Genetic Signatures Limited (GSS) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Genetic Signatures Limited (GSS) ORDINARY FULLY PAID	Health Care	$13	Quarterly Activities/Appendix 4C Cash Flow Report	23 Jul 2026 2:11PM	$0.059	$0.058	fallen by 1.69%
Genetic Signatures Limited (GSS) ORDINARY FULLY PAID	Health Care	$13	Becoming a substantial holder from BDX	2 Jul 2026 5:13PM	$0.065	$0.058	fallen by 10.77%
Genetic Signatures Limited (GSS) ORDINARY FULLY PAID	Health Care	$13	GSS responds to the BCAL Diagnostics Announcement	2 Jul 2026 2:41PM	$0.066	$0.058	fallen by 12.12%
Genetic Signatures Limited (GSS) ORDINARY FULLY PAID	Health Care	$13	BDX: BCAL to Acquire Shares in Genetic Signatures	2 Jul 2026 10:04AM	$0.068	$0.058	fallen by 14.71%
Genetic Signatures Limited (GSS) ORDINARY FULLY PAID	Health Care	$13	Ceasing to be a substantial holder	1 Jul 2026 12:20PM	$0.067	$0.058	fallen by 13.43%
Genetic Signatures Limited (GSS) ORDINARY FULLY PAID	Health Care	$13	Change of Company Secretary	19 Jun 2026 8:58AM	$0.067	$0.058	fallen by 13.43%

GSS Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$12.73	-$5.60	-48.00%	0.00%	0.0%
2024A	-$17.86	-$10.80	13.00%	0.00%	0.0%
2023A	-$14.05	-$9.60	-564.60%	0.00%	0.0%

GSS Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Genetic Signatures Limited (GSS)	$13M	-0.4801	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%

GSS Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	0.26	0.00
Market	0.31	13.10	1.15	0.65
Sector	0.49	33.50	2.47	2.59

GSS Directors

Name	Position	Start Date
Mr Michael Anton Aicher	Executive Director - US Operations	16 May 2014
Dr Jenny Lee Harry	Non-Executive Director	1 Oct 2024
Ms Anne Nicole Lockwood	Non-Executive Director	1 Oct 2024
Ms Caroline Waldron	Non-Executive Director, Non-Executive Chairman	13 May 2022

Genetic Signatures Limited (GSS) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
16 Dec 2024	AICHER, Michael	Issued	Direct Shares	66,666	$0.750	$49,999.500
8 Jul 2024	CHATONSKY, Stephane	Issued	Indirect Shares	27,750	$0.750	$20,812.500
8 Jul 2024	WALDRON, Caroline	Issued	Direct Shares	3,302	$0.750	$2,476.500

See all changes in directors' interest & trades for Genetic Signatures Limited (GSS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

GSS Management

Name	Position
Allison Rossiter	--
Sonya Tissera-Isaacs	Company Secretary

GSS Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Genetic Signatures Limited (GSS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
44,949,035 (19.79%)	Asian Union Investment Pty Limited
33,476,488 (14.74%)	Perennial Value Management Limited
20,138,177 (8.87%)	Regal Funds Management Pty Ltd
18,341,646 (8.08%)	FIL Limited and the entities

GSS Calendar of Events

Date	Event
25 February 2027	Report (Interim)
24 August 2026	Report (Annual)
24 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us